Allogene Therapeutics, Inc.
ALLOHealthcare|Biotechnology|US
$1.04
-0.05 (-4.59%)
Tangible Book / Share
$1.13
Cash / Share
$0.85
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06500273 Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Large B-cell Lymphoma | P2 | Recruiting | 250 | RCT, Open-label | Fludarabine, Cyclophosphamide |
| NCT04416984 Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | P1P2 | Active | 160 | Open-label | ALLO-647, Fludarabine, Cyclophosphamide |
| NCT04696731 Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | P1 | Active | 120 | Open-label | ALLO-647, Fludarabine, Cyclophosphamide |
| NCT07085104 A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | P1 | Recruiting | 66 | Open-label | Cyclophosphamide, Fludarabine |
| NCT05714345 Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy | Relapsed/Refractory Large B Cell Lymphoma | P2 | Terminated | 2 | RCT, Open-label | ALLO-647, Fludarabine, Cyclophosphamide |
| NCT05000450 Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1P2 | Terminated | 6 | Open-label | ALLO-647, Fludarabine, Cyclophosphamide |
| NCT04093596 Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) | Relapsed/Refractory Multiple Myeloma | P1 | Completed | 73 | Open-label | ALLO-647, Fludarabine, Cyclophosphamide, Nirogacestat |
| NCT03939026 Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma | Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma | P1 | Completed | 50 | Open-label | ALLO-647, Fludarabine, Cyclophosphamide |
| NCT06925685 Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product | Hematologic Malignancies, Solid Tumors | By Invite | 50 | — | — |